Metraipolis › archive › dc_41bd28032f7d
Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States — Europe PMC PMID:42188782
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42188782
- DOI
- 10.3390/vaccines14050411
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T19:47:27.604Z
- SHA-256 of the archived text
da5bbf7c9142adad05e82f0a93233635e1f1f6aec967201905f6fff96966c935- Stable URL of this page
https://metraipolis.com/documento/dc_41bd28032f7d
How to cite
Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States — Europe PMC PMID:42188782 — Europe PMC (en), https://europepmc.org/article/MED/42188782 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_41bd28032f7d (Metraipolis archive dc_41bd28032f7d, sha256 da5bbf7c9142adad05e82f0a93233635e1f1f6aec967201905f6fff96966c935)
BibTeX
@misc{dc41bd28032f7d,
title = {Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States — Europe PMC PMID:42188782},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42188782},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_41bd28032f7d; sha256 da5bbf7c9142adad05e82f0a93233635e1f1f6aec967201905f6fff96966c935},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42188782. Agents can read the archived copy with the MCP tool read_document.